Hybrigenics is developing inecalcitol as a niche therapy in adult leukaemia. Disease progression slowed in 52% of patients treated in a Phase II chronic lymphocytic leukaemia (CLL) trial. We have increased our valuation from €108m to €143m as we assume that Hybrigenics will self-fund approval studies in leukaemia and achieve higher royalties vs our previous assumption. If the company advances inecalcitol into Phase II/III CLL studies there is upside scope to €173m.
28 Jul 2015
Taking inecalcitol across the Atlantic
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Taking inecalcitol across the Atlantic
Hybrigenics SA Class A (ALHYG:PAR) | 0 0 0.0% | Mkt Cap: 25.2m
- Published:
28 Jul 2015 - Author:
- Pages:
Hybrigenics is developing inecalcitol as a niche therapy in adult leukaemia. Disease progression slowed in 52% of patients treated in a Phase II chronic lymphocytic leukaemia (CLL) trial. We have increased our valuation from €108m to €143m as we assume that Hybrigenics will self-fund approval studies in leukaemia and achieve higher royalties vs our previous assumption. If the company advances inecalcitol into Phase II/III CLL studies there is upside scope to €173m.